



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No: 37945-0018

Applicant: Angus George DALGLEISH *et al.* Confirmation No.: 6462
Appl. No.: 09/857,691 Examiner: M. Davis
Filing Date: September 5, 2001 Group Art Unit: 1642
Title: USE OF HUMAN PROSTATE CELL LINES IN CANCER
TREATMENT

Response / #12
6.17.03
RECEIVED
JUN 12 2003
TECH CENTER 1600/2900

RESPONSE TO SPECIES REQUIREMENT

Commissioner for Patents
Washington, D.C. 20231


Sir:

In response to the office action mailed April 22, 2003, applicants hereby elect with traverse the following species: [1] "(a) induction of a decrease in the rate of rise" parameter and [2] the cell lines PNT2, LnCaP and NIH-1542. Applicants request examination of other species in accordance with the Patent Office regulations.

A first office action on the merits is awaited.

Respectfully submitted,

May 21, 2003
Date



John P. Isacson
Reg. No. 33,715

HELLER EHRMAN WHITE & McAULIFFE LLP
1666 K Street, N.W., Suite 300
Washington, D.C. 20006
Tel: 202-912-2000
Fax: 202-912-2020



26633